Abstract PS2-06-30: Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with HER2-negative recurrent high-risk early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness)
Abstract PS2-06-30: Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with HER2-negative recurrent high-risk early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness)
Takayuki Iwamoto, Tomoe Taji, Aki Ito, Yuichiro Kikawa et al.
Journal
Clinical Cancer Research
Topics
PARP inhibition in cancer therapy
article
Abstract PS2-06-30: Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with HER2-negative recurrent high-risk early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness)
Takayuki Iwamoto, Tomoe Taji, Aki Ito, Yuichiro Kikawa, Ryoichi Matsunuma, Mikiko Uemura, Hirohito Seki, Yuri Kimura, Noriko Maeda, Daisuke Takabatake, C. Koganezawa, M. Harao, H. Mukai, S. Nakamoto
article en
Abstract
No abstract available for this paper.
Publication Tag
Clinical Cancer ResearchVol. 32(4_Supplement)
Institutions
Kansai Medical University (JP), Jichi Medical University (JP), Yamaguchi University (JP), Kawasaki Medical School (JP), Okayama University Hospital (JP), Institute for Health Economics and Policy (JP), Shizuoka General Hospital (JP), Akita Red Cross Hospital (JP), Kyorin University Hospital (JP), Shikoku Cancer Center (JP), Hokkaido University Hospital (JP), National Cancer Center Hospital East (JP), Japanese Foundation For Cancer Research (JP)